Psychedelic Therapy Sector A Health and Economic Development Initiative focused on a regulated, evidence-led approach designed to improve patient outcomes and deliver sustainable economic value for the Bailiwick of Guernsey.

Better treatment for Islanders. A new industry for the Island.

Evidence. Control. Opportunity.

A case for the Island to establish a regulated Neurotherapy sector, delivering treatment for Islanders whom current medicine is failing, and a new high-value industry for the Island economy.

What Neurotherapy Guernsey is, and what it sets out to achieve

The purpose of Neurotherapy Guernsey is to establish an entirely new, self-sufficient economic sector for the Island, built at the point where health outcomes and economic growth reinforce one another rather than compete.

The Island holds full legislative autonomy over drug regulation, can act at a speed larger jurisdictions cannot match, and already possesses the professional and financial infrastructure the sector requires. The aim is twofold and inseparable: to give Islanders access to treatments that current pathways demonstrably fail to deliver, and to build a durable, export-led sector that diversifies an economy dependent on financial services for thirty-seven per cent of its GDP.

Four areas carry the argument.

The case in four parts
Part 101 / 04

The Psychedelic for Health sector

The global scientific, clinical and commercial forces now reshaping psychiatric medicine, and why this is no longer a fringe field.

1. The Psychedelics Landscape

This is not a fringe alternative therapy or a homeopathic curiosity.

It is a global scientific and pharmaceutical drive towards redefining the treatment of mental illness, and it is arguably the single largest shift in psychiatric medicine in a hundred years.

The world’s most valuable pharmaceutical company committed up to $3.8 billion to the field three weeks ago. The President of the United States signed an Executive Order to accelerate it in April.

The question facing the Island is not whether this is happening, but whether it participates in it.

1.1

Purpose and objectives of the sector

  1. 01

    To provide effective treatment for conditions that current psychiatry demonstrably fails to resolve

    Treatment-resistant depression, PTSD, addiction, and end-of-life distress.

  2. 02

    To move from maintenance to resolution

    A one-to-three session intervention producing durable change, rather than daily medication taken indefinitely.

  3. 03

    To secure full regulatory approval

    Phase 3 trials are underway across multiple compounds, with FDA submissions expected within the current cycle.

  4. 04

    To build the clinical infrastructure

    Trained facilitators, supervised settings, preparation and integration protocols, without which the compounds do not work.

1.2

Who is driving it

Countries

United States (federal Executive Order, FDA Breakthrough designations, state programmes in Oregon and Colorado), Australia (first nation to permit prescribing, from July 2023), Czech Republic (first EU medical framework, January 2026), Germany, Switzerland, New Zealand, Canada and the Netherlands.

Pharmaceutical

Eli Lilly (acquired AtaiBeckley), Johnson & Johnson (Spravato, approaching $2bn in sales), AbbVie (up to $1.2bn for Gilgamesh Pharmaceuticals’ lead candidate), Compass Pathways, Definium Therapeutics, Lykos Therapeutics, MindMed, Jazz Pharmaceuticals.

The pattern is consistent

Specialist biotechs are being acquired by major pharmaceutical companies at significant premiums, which is the standard signal that a therapeutic class has moved from speculative to strategic.

1.3

Academic institutions and leading researchers

0 100+
Psychedelic research being conducted in the UK before 2009 Studies running each month worldwide
  • Imperial College London

    Centre for Psychedelic Research, the world’s first, founded 2019 with over £3m from five donors, based at Hammersmith Hospital in partnership with Imperial College Healthcare NHS Trust.

  • Johns Hopkins University

    Center for Psychedelic and Consciousness Research, launched with $17m of private funding; the largest research hub of its kind.

  • Also active

    NYU Langone, University of California San Francisco, King’s College London, Maastricht University, Australian National University (national outcomes registry).

  • Leading figures

    Professor David Nutt and Dr Robin Carhart-Harris (Imperial, now also UCSF); the late Professor Roland Griffiths and Professor Matthew Johnson (Johns Hopkins); Dr James Rucker (King’s College London).

  • Scale of activity

    From no psychedelic research being conducted in the UK before 2009, to more than one hundred studies running each month worldwide.

1.4

The economic landscape

August 2025AbbVie
up to $1.2bn

AbbVie paid up to $1.2bn for Gilgamesh Pharmaceuticals’ lead psychedelic candidate.

March to July 2026NASDAQ: ATAI

AtaiBeckley traded at approximately $3.30 in late March 2026 and was acquired at $6.75 per share in July. Roughly a doubling in four months.

July 2026Eli Lilly
up to $3.8bn

Eli Lilly agreed to acquire AtaiBeckley: $2.8bn upfront at $6.75 per share, a 40% premium to the 30-day average, plus up to $1.0bn in milestone payments. The largest transaction the sector has seen.

Annual salesJohnson & Johnson
close to $2bn

Spravato, an in-clinic, monitored, psychedelic-adjacent therapy, has already reached close to $2bn in annual sales, proving the commercial model works.

This is a NASDAQ-listed, institutionally-held, index-included sector.

AtaiBeckley was included in the S&P Total Market Index. Compass Pathways, Definium Therapeutics, LB Pharmaceuticals and Psyence Biomedical are all NASDAQ-listed. These are not fringe vehicles.

1.5 · Global sector value
$23bnBy 2035
  • Ten years agoEffectively pre-commercial. The first FDA Breakthrough Therapy designation for psilocybin came in 2018; the first dedicated academic research centres opened in 2019.
  • TodayApproximately $6.7bn globally in 2026.
  • Ten years from nowApproximately $23bn by 2035, at a compound growth rate of around 15%. Estimates across research houses range from $12bn to $26bn, but every published forecast projects a three-to-fivefold increase.
1.6

Two developments that changed the picture

US Executive Order18 April
2026

President Trump signs Executive Order on psychedelic therapy

Directs the FDA to issue National Priority Vouchers for qualifying psychedelic drugs, establishes a Right to Try pathway, allocates $50m through ARPA-H to match state investment, and tasks the Attorney General with initiating rescheduling reviews once Phase 3 trials complete.

For the sector globally, this converts psychedelic medicine from a research question into declared federal policy, and it puts a visible timetable on US rescheduling, which is the event that will open the market.

Eli Lilly acquisition$3.8bn

Eli Lilly acquires AtaiBeckley, 16 July 2026

The lead asset is BPL-003, an intranasal synthetic form of 5-MeO-DMT for treatment-resistant depression, holding FDA Breakthrough Therapy Designation with Phase 3 underway.

The world’s most valuable pharmaceutical company has taken a direct position in psychedelic medicine at the largest valuation the sector has ever seen. That is the institutional validation the field has been waiting a decade for.

1.7

The medicines and how they are administered

Two distinct models exist, and they should not be confused with one another.

The model this proposal is built on

Supervised therapeutic dose

A single substantial dose administered in a prepared clinical setting with a trained facilitator present throughout, preceded by preparation sessions and followed by structured integration. This is the model used in the Johns Hopkins, Imperial and NYU trials, and by legal retreat operators in the Netherlands and Jamaica using psilocybin truffles. It is the model with the clinical evidence behind it, and the model this proposal is built on.

An area of active research

Microdosing

Sub-perceptual doses taken on a repeating schedule, commonly five days in seven, producing no intoxication and no impairment of normal function. It is very widely practised. The published evidence base is, however, materially weaker than for the supervised therapeutic dose: several placebo-controlled trials have found that reported benefits are largely attributable to expectancy effects. It should be presented as an area of active research rather than as established therapy.

Beyond psilocybin

The pipeline now reaches from discovery to Phase 3.

The sector name Neurotherapy is deliberate: it accommodates all of these without requiring the word psychedelic to appear in a policy document.

Part 202 / 04

The Problems Facing the Island

Mental & Physical Health. ‘The Core 8’. The eight conditions carrying the greatest mental and physical health burden on the Island, and what they cost the States and the wider economy each year.

2. Mental and Physical Health: The Core 8

Eight conditions account for the overwhelming share of the mental and physical health burden carried by the Island.

They are substantially understated in public discussion and in the figures the States routinely sees, because most of their cost never appears as a line in a health budget: it surfaces instead as lost earnings, reduced productivity, unpaid family care and premature withdrawal from the workforce.

The Island holds very little condition-level data of its own, so the figures below are extrapolated from United Kingdom prevalence at a population ratio of approximately 1:1,080 unless marked otherwise.

Every one of the eight is increasing, in every measure for which a time series exists.

The Core 8 01 / 08
The total

Combined burden of the Core 8

Cost to the States £70m per year
Direct public expenditure on health, social care, criminal justice and benefits administration across all eight conditions.
Cost to the Island £175m per year
The above plus lost earnings, lost tax, reduced productivity and unpaid family care.

Figures are discounted for overlap between conditions. Chronic pain and depression, PTSD and addiction, and dementia and palliative care all share substantial patient populations, so the individual figures above should not simply be summed. Case numbers reflect diagnosed or measured prevalence while costs are modelled on the clinically affected population; the two should not be divided against one another.

Part 303 / 04

An Overview of the Neurotherapy Guernsey Sector

The six core pillars driving the proposal, and why each matters to the Island irrespective of this sector.

3. Six core pillars

The Neurotherapy Guernsey sector is not an opportunistic response to a regulatory gap.

It is built to deliver against six core pillars, each of which describes something the Island needs irrespective of this proposal, and each of which this sector is unusually well suited to serve. The pillars are the drivers: every capability described in the previous section exists because it advances one or more of them, and any element of the sector that cannot be tied back to a pillar has no place in it.

They are set out below in the order in which they were conceived, not in order of importance, because the argument for the sector rests on all six together rather than on any one of them alone.

  1. 01

    Centre of Excellence

    The Island has the scale, the regulatory agility and the professional infrastructure to become a recognised international centre in a field that is still forming, and being known for something is worth more to a small jurisdiction than being adequate at many things.

  2. 02

    Sustainability of Existing Infrastructure

    The Island already holds redundant glasshouse estate, vacant light commercial premises and out-of-season visitor accommodation; putting these back into productive use is a better outcome for the Island than allowing them to decline further, and it costs the States nothing to enable.

  3. 03

    Island-wide Fiscal Growth and Prosperity

    An economy that depends on financial services for thirty-seven per cent of its GDP carries a concentration risk that no amount of good management inside that sector can offset, and genuine diversification requires building something new rather than optimising what exists.

  4. 04

    Mental and Physical Health Betterment

    A significant number of Islanders live with depression, post-traumatic stress, addiction, chronic pain and end-of-life distress that current treatment pathways demonstrably fail to resolve, and this is the pillar on which the moral case for the entire sector rests.

  5. 05

    Job Creation

    The Neurotherapy Guernsey sector creates employment across the full range of the economy: secure entry-accessible roles in cultivation and site operations, skilled technical roles in manufacturing and laboratory work, and senior clinical and scientific roles that give Islanders working off-Island a reason to return.

  6. 06

    Global Enterprise and Integration

    The Island’s long-term relevance depends on remaining connected to industries that are growing rather than defending those that are mature, and a regulated Neurotherapy Guernsey sector connects the Island to global research, capital and clinical networks that it currently sits outside.

The argument for the sector rests on all six together rather than on any one of them alone.

Part 404 / 04

Neurotherapy Guernsey Sector Ecosystem Summary

The twelve capabilities that make up the sector, their annual value to the Island, and the employment each would create.

4. Sector Ecosystem Summary
12interconnecting capabilities
£52mcentral-case sector value a year, at maturity
375new jobs
£97–102mtotal annual value to the Island

The purpose of Neurotherapy Guernsey is to establish an entirely new, self-sufficient economic sector for the Island, built at the point where health outcomes and economic growth reinforce one another rather than compete.

Neurotherapy, the regulated research, manufacture and supervised clinical application of psilocybin and related compounds, is one of the fastest-moving areas of global medicine, and no jurisdiction in the British Isles has yet moved to capture it.

The Island holds full legislative autonomy over drug regulation, can act at a speed larger jurisdictions cannot match, and already possesses the professional and financial infrastructure the sector requires. The aim is twofold and inseparable: to give Islanders access to treatments that current pathways demonstrably fail to deliver, and to build a durable, export-led sector that diversifies an economy dependent on financial services for thirty-seven per cent of its GDP.

The Neurotherapy Guernsey sector would not be built from nothing. It draws on assets the Island already holds and currently underuses, and connects them to new capability in research, manufacturing, clinical care and training. Twelve interconnecting capabilities make up the sector, each viable in its own right but materially stronger for the presence of the others.

  • Assets the Island already holds
  • Redundant glasshouse estate
  • Vacant light commercial premises
  • Out-of-season visitor accommodation
  • A mature funds and insurance industry
4.1

The twelve capabilities

Each block is sized by its annual value to the Island. Select a block for the detail.
The full list

Value and employment, capability by capability

Figures are central-case estimates of gross annual value to the Island economy at sector maturity, taken as approximately ten years from the commencement of enabling legislation. Conservative and ambitious scenarios are set out in the supporting economic assessment. Headcount is not additive across capabilities: head-office and corporate roles are counted in capability 3, while technical, clinical and production roles sit in capabilities 1, 2, 5 and 6. No figure includes indirect or induced multiplier effects.

New jobs at maturity375From secure, entry-accessible roles in cultivation and site operations to senior clinical and scientific roles.
4.2

Secondary financial gains

The figures above cover the sector itself. They exclude two further categories of value that would arise as a consequence of it.

Health and care cost avoidance
£14m

to the States, and £35m to the Island economy

The eight priority conditions cost the States an estimated £70m a year, and the Island economy around £175m.

Based on the sector delivering a sustained positive impact on 20% of the Island’s mental and physical health burden.

Wider Island value and buoyancy
£10–15m

a year, plus a one-off £40m capital uplift

Reactivation of redundant vinery, glasshouse and light commercial sites, recovery of out-of-season accommodation, and increased visitor demand from the Island’s exposure as a holistic destination on a global stage.

Illustrative sensitivities rather than forecasts, and the least certain figures in this document. The twenty per cent assumption is a modelling scenario, not a clinical claim. Presented separately from the £52m so the two are not conflated.

The total · per annumSector value
£97–102m
Total annual value to the Island
To the Island£97–102m
£52m£35m£10m
Sector valueHealth and care cost avoidanceWider Island value and buoyancy, £10–15m
Total net benefit to the States£21m
£7.3m£14m
Returns directly to the StatesHealth and care cost avoidance to the States